IQ Therapeutics receives follow-on investments from DSM and NOM for innovative treatment of infectious diseases

29-Mar-2012 - Netherlands

Royal DSM and NOM Finance have made a follow-on investment in IQ Therapeutics BV, a Netherlands-based biotech company that develops antibodies, effective in combating life-threatening infectious diseases. Financial details of the investment will not be disclosed.  

“DSM has been an investor since 2008 and believes in the potential of IQ Therapeutics’ unique development products that are addressing a number of serious unmet needs.” says Marcel Lubben, VP Venturing & Licensing at DSM. DSM is a partner of IQ Therapeutics in the process development and manufacturing of its innovations, especially using the PER.C6® human cell line. “It is a fertile partnership for both parties as it allows the IQ Therapeutics’ antibodies to be produced at a competitive cost-of-goods level.”

The technology “Cloning the Human Response”, invented by IQ Therapeutics is developing a range of antibodies to address diseases including the highly dangerous anthrax and the Methicillin Resistant Staphylococcus aureus (MRSA) infection.

“With our fully human antibodies within anthrax and MRSA, IQ Therapeutics has promising applications in the pipeline.” says IQ Therapeutics CEO, Michael Pålsson. “An important milestone has been achieved with the proven clinical safety of the antibodies generated with our technology. With the demonstrated efficacy, we are confident that IQ Therapeutics’ anthrax drug in development will have both the potential to extend the time to treatment and increase the survival rate compared to other drug developments. With infectious diseases in healthcare settings becoming one of the most significant healthcare challenges, I am excited by our MRSA project. It has the potential to improve the quality and standard of care through an earlier recovery with higher survival rate at a reduced healthcare cost.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous